Back to Search Start Over

Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes

Authors :
Maria Helena Andrade Santana
Arlete Aparecida Martins Coelho-Castelo
Célio Lopes Silva
Carlos R. Zárate-Bladés
Rogério Silva Rosada
Fabiani Gai Frantz
Izaíra T. Brandão
Edson Garcia Soares
Lúcia Helena Faccioli
Lucimara Gaziola de la Torre
Ana Paula Favaro Trombone
Simone G. Ramos
Denise Morais da Fonseca
Ana Paula Masson
Patricia R. M. Souza
Source :
BMC Immunology, BMC Immunology, Vol 9, Iss 1, p 38 (2008)
Publisher :
Springer Nature

Abstract

BackgroundThe greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally.ResultsWe developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg).ConclusionOur objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.

Details

Language :
English
ISSN :
14712172
Volume :
9
Issue :
1
Database :
OpenAIRE
Journal :
BMC Immunology
Accession number :
edsair.doi.dedup.....6307bf542f192377f340255925237ba8
Full Text :
https://doi.org/10.1186/1471-2172-9-38